ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC) Meeting Abstract
| Authors: | Banerjee, S. N.; Monk, B. J.; Van Nieuwenhuysen, E.; Moore, K. N.; Oaknin, A.; Fabbro, M.; Colombo, N.; O'Malley, D. M.; Coleman, R. L.; Pachter, J. A.; Koustenis, A. G.; Patrick, G.; Leonard, L.; Grisham, R. N. |
| Abstract Title: | ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120306319 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS5603 |
| Notes: | Meeting Abstract: TPS5603 -- Source: Wos |
